Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Filters applied: . Clear all
Page 1
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK; HERCULES Investigators. Scully M, et al. N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9. N Engl J Med. 2019. PMID: 30625070 Free article. Clinical Trial.
Key secondary outcomes included a composite of TTP-related death, recurrence of TTP, or a thromboembolic event during the trial treatment period; recurrence of TTP at any time during the trial; refractory TTP; and normalization of organ-d …
Key secondary outcomes included a composite of TTP-related death, recurrence of TTP, or a thromboembolic event during the t …
Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura.
Elverdi T, Eskazan AE. Elverdi T, et al. Drug Des Devel Ther. 2019 Apr 17;13:1251-1258. doi: 10.2147/DDDT.S134470. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31118566 Free PMC article. Review.
The drug was first developed for the prevention of thrombosis in high-risk patients with acute coronary syndrome undergoing percutaneous coronary intervention; however, drug development for this indication has been discontinued. Recently, caplacizumab received its first ap …
The drug was first developed for the prevention of thrombosis in high-risk patients with acute coronary syndrome undergoing percutaneous cor …
Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial).
Estcourt LJ. Estcourt LJ. Transfus Med. 2019 Jun;29(3):146-148. doi: 10.1111/tme.12615. Transfus Med. 2019. PMID: 31318128 Clinical Trial.
CLINICAL QUESTION: In people with acquired thrombotic thrombocytopenic purpura (TTP), does caplacizumab decrease the time to normalisation of the platelet count and the risk of death and complications caused by thrombotic events and organ damage? EVIDENCE FRO …
CLINICAL QUESTION: In people with acquired thrombotic thrombocytopenic purpura (TTP), does caplacizumab decrease the ti …